Gastrointestinal Cancer

胃肠癌

• 批准号: 9282706
• 负责人: KAREN E KNUDSEN
• 金额: $ 3.83万
• 依托单位: THOMAS JEFFERSON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-06-01 至 2018-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9282706
• 关键词: Adjuvant Therapy; Biological Markers; Cancer Biology; Cancer Center; Cancer Control; Chemoprevention; Clinical; Clinical Trials; Clinical Trials Design; Collaborations; Colorectal Cancer; Diagnosis; Diagnostic; Diagnostic Trial; Disease; Early Diagnosis; Enrollment; Epigenetic Process; Evidence based practice; Family Practice; Funding; Goals; Healthcare Systems; Hormones; Immunotherapeutic agent; In Vitro; Inflammation; Instruction; Internal Medicine; Intestines; Laboratories; Malignant Neoplasms; Malignant neoplasm of esophagus; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of liver; Malignant neoplasm of pancreas; Medical Oncology; Micronutrients; Modality; Molecular; Molecular Genetics; Neoplasm Metastasis; Neoplasms; Operative Surgical Procedures; Organ; Paper; Pathology; Patients; Peer Review; Pharmacology; Population; Postoperative Period; Prevention; Process; Publications; Publishing; Radiology Specialty; Research; Research Personnel; Risk stratification; Role; Scientist; Staging; Stem cells; Therapeutic; Therapeutic Trials; Translating; Translational Research; Translations; Universities; Work; base; cancer chemoprevention; cancer prevention; clinical application; clinical development; cohesion; gastrointestinal; improved; in vivo; individual patient; innovation; medical schools; member; molecular targeted therapies; multidisciplinary; novel; novel diagnostics; novel therapeutics; outcome forecast; paracrine; patient population; predictive marker; prevent; prognostic; programs; racial disparity; tool; tumorigenesis

PROJECT SUMMARY (See Instructions): The Gastrointestinal (Gl) Cancer Program (Program #6), one of the original programs of the Kimmel Cancer Center at Jefferson, is a multidisciplinary program composed of 25 full and 5 associate members representing 8 departments within Jefferson Medical College (Pathology; Cancer Biology; Family Medicine; Internal Medicine; Medical Oncology; Pharmacology; Radiology; Surgery), the Christiana Care Health System (Helen F. Graham Cancer Center), and Drexel University, whose over-arching goal is to define fundamental mechanisms underlying Gl malignancies which can be translated into diagnostic and therapeutic innovations for managing cancer in patients and populations. Their work is supported by �~$7.7M in peer-reviewed funding, representing an increase of -75% from $4.4M during the past funding period. Also, program members have published 561 papers, representing almost a doubling compared to the previous funding period. Of those, >17% were intra-programmatic, representing a tripling of the previous rate, and >16% were inter-programmatic. Program members pursue parallel efforts organized along organ based disease processes from discovery through translation to clinical development and application. Members employ common and collaborative experimental paradigms with the goals of (1) defining previously unappreciated molecular, genetic, and epigenetic mechanisms underlying Gl organ-based tumorigenesis, (2) translating defined mechanisms into novel in vitro and in vivo tools to improve prevention, early detection, prognosis, prediction, and risk-stratification in Gl malignancies, (3) defining molecularly targeted therapeutic approaches for cancer prevention, treatment, and control, (4) advancing novel laboratory discoveries into development for clinical trials, and (5) advancing clinically successful diagnostic and therapeutic trials into evidence-based practice for cancer prevention and control across populations. In that context, enrollment of patients in Gl cancer-based clinical trials has increased ~15-fold compared to the past funding period. Members are interactive and cohesive and, under the direction of Program Leaders, coordinate research planning and new research directions with other research programs in the Cancer Center.

项目摘要（参见说明）： 胃肠道 (GI) 癌症计划（计划 #6）是杰斐逊金梅尔癌症中心的原始计划之一，是一个多学科计划，由代表杰斐逊医学院 8 个系（病理学、癌症生物学、家庭医学、内科、肿瘤内科、药理学、放射学、外科）、Christiana Care Health System（Helen F. Graham 癌症中心）和 Drexel 的 25 名正式成员和 5 名准成员组成。 大学的首要目标是定义 胃肠道恶性肿瘤的基本机制可以转化为管理患者和人群癌症的诊断和治疗创新。他们的工作得到了 770 万美元的同行评审资金支持，比过去资助期间的 440 万美元增加了 -75%。此外，项目成员发表了 561 篇论文，几乎比上一个资助期增加了一倍。其中，>17% 是项目内的，是之前的三倍，>16% 是项目间的。计划成员沿着基于器官的疾病过程，从发现到转化，再到临床开发和应用，进行并行的努力。 成员采用共同和协作的实验范式，其目标是（1）定义以前未认识到的基于胃肠道器官的肿瘤发生的分子、遗传和表观遗传机制，（2）将定义的机制转化为新的体外和体内工具，以改善胃肠道恶性肿瘤的预防、早期检测、预后、预测和风险分层，（3）定义分子靶向 癌症预防、治疗和控制的治疗方法，(4) 将新的实验室发现推进到临床试验的开发中，(5) 将临床成功的诊断和治疗试验推进到基于证据的实践中，以预防和控制跨人群的癌症。在这种情况下，与过去的资助期相比，参加基于 GI 癌症的临床试验的患者人数增加了约 15 倍。成员具有互动性和凝聚力，在项目负责人的指导下，与癌症中心的其他研究项目协调研究规划和新的研究方向。